Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases



Maternal RSV Vaccine Implementation Considerations

Georgina Peacock, MD, MPH
Immunization Services Division
Centers for Disease Control and Prevention

Maternal RSV Implementation Considerations


- Vaccine storage, handling, and administration
- Cost of vaccine
- Insurance coverage
- Supply and availability
- Complexity of immunization schedule
- Vaccine demand and coverage in pregnant people
- Obstetric and pediatric provider roles in vaccination decisions
- Immunization information systems
- Communication challenges



Pfizer RSV Vaccine Storage, Handling, and Administration

- Overall clinical implementation similar to other vaccines
 - Stored at 2° to 8° C
 - Administered as a single dose through intramuscular route
- Additional steps required for dilution, including reconstitution of the lyophilized antigen component with the sterile water diluent component

Supplied as a kit with the following components:



Proposed recommendations to ACIP allow for simultaneous administration with other recommended vaccines


Increasing number of vaccines could lead to concerns for limited storage space

Cost of Maternal RSV Vaccine

- Cost of the Pfizer RSV vaccine is \$295/dose, compared to ~\$46-52 for Tdap¹
 - Cost is lower than infant nirsevimab (\$495 private sector cost)
- Reimbursement and cost recovery challenges already identified by providers and practices as an implementation barrier for maternal immunization²

- 1. Current CDC Vaccine Price List CDC
- 2. <u>Immunization Practices of U.S. Obstetrician/Gynecologists for Pregnant Patients | ScienceDirect</u>

Provider Financial Concerns are a Leading Barrier to Maternal Immunization



Insurance Coverage of Maternal RSV Vaccine

- Private insurance: 52% of pregnant people¹
 - The Affordable Care Act (ACA) requires insurers to cover all ACIP-routinely recommended immunizations for plan years that begin on or after the date that is one year after the date of the recommendation²
- Medicaid: 41% of pregnant people¹
 - After 10/1/23, when the Inflation Reduction Act provisions become effective, state Medicaid agencies will be required to cover vaccines and their administration without cost-sharing for nearly all fullbenefit adult beneficiaries covered under traditional Medicaid, if the CDC/ACIP recommendations apply³
- No insurance: 4% of pregnant people "self-pay" (likely uninsured)¹
 - If recommended, ACIP will vote on a Vaccines for Children resolution for maternal RSV vaccine in people aged <19 years
 - For people age 19+ years, limited availability (e.g., through 317 program)
- 1. Products Data Briefs Number 468 May 2023 (cdc.gov); insurance status refers to source of payment for delivery. Another ~3% used other types of coverage
- 2. 42 U.S. Code § 300gg-13 Coverage of preventive health services | Cornell Law School
- 3. Anniversary of the Inflation Reduction Act: Update on CMS Implementation | CMS

Insurance Coverage for Infant Nirsevimab

 ACIP has recommended nirsevimab as a routine immunization. Therefore, it will be covered under the ACA without cost sharing by the patient starting in the effective plan year¹


- Nirsevimab is included in the Vaccines for Children Program²
 - Eligible children (~50% of U.S. children) will be able to access nirsevimab at no cost

- 1. 42 U.S. Code § 300gg-13 Coverage of preventive health services | Cornell Law School
- 2. Advisory Committee on Immunization Practices, Vaccines for Children Program | CDC

Supply and Availability of Maternal RSV Vaccine and Nirsevimab During 2023–2024 RSV Season


- No anticipated supply/demand mismatch
- Because the Pfizer maternal RSV vaccine is the same product in use for adults aged
 ≥60 years, availability is expected shortly after ACIP recommendations
- Nirsevimab will likely be available late September/early October, but may not be available in all pediatric settings this season
 - Efforts underway to increase number of birthing hospitals who will administer nirsevimab

Increasing Complexity of Maternal Immunization Schedule




- Increasingly complex maternal immunization schedule, with different timing of vaccines based on season and/or gestational age (with seasonal timing varying in some locations)
- Limited window for RSV vaccine administration
- Unclear willingness of pregnant people to accept multiple vaccines in pregnancy

In a survey of pregnant people, 12% said they would accept no vaccines, and 49% said they would accept 1-2 vaccines



Uptake of Vaccines among Pregnant People Has Declined and Disparities Persist



Obstetric Provider Role in Immunization Decisions

- Decisions for whether to administer maternal RSV vaccine or infant nirsevimab will need to be made during pregnancy
- Studies continue to demonstrate healthcare providers as pregnant people's most trusted source of information on vaccines, and provider recommendation is a strong predictor of vaccination¹
- However, one survey showed that 2/3 of obstetricians did not feel providing information about routine childhood immunizations was part of their role²

- 1. Lutz C, et al. Understanding barriers and predictors of maternal immunization: Identifying gaps through an exploratory literature review. Vaccine 36 (2018): 7445-7455
- 2. Missed Opportunities: A National Survey of Obstetricians About Attitudes on Maternal and Infant Immunization | SpringerLink

Pediatric Provider Role in Immunization Decisions

 Recommendations for nirsevimab that are contingent upon knowledge of maternal vaccination status could be challenging if the pediatric provider does not receive the maternal record

- Verbal report of vaccines received during pregnancy may not be reliable¹
- Pediatric providers may need to make decisions on nirsevimab administration with incomplete information on maternal vaccination status

Immunization Information Systems (IIS)

- State IIS vary in adult immunization capture
- Pregnancy status not identified in IIS, though could potentially consider RSV vaccine administrations in adult women (<age 60 years) as a proxy
- Unable to link maternal and infant immunization records in the IIS
 - Clinical Decision Support for immunization unable to take into account maternal vaccination history for forecasting for infant nirsevimab immunization
 - Some state IIS policies limit ability of pediatric providers to review adult records, or records for individuals who are not their patients

Communications Challenges

- Terminology: Vaccine (maternal product) vs.
 Immunization (infant product)
- Conveying potential risks and benefits of each approach, and helping the pregnant person make an informed decision
 - Including potential but undetermined risk of preterm birth with maternal immunization
- Discussing financial implications to patient in setting of uncertainties about coverage during the first year of implementation



Communications Activities

- Formative Research and Message Testing:
 - Focus groups and in-depth interviews with pregnant people and prenatal health providers (in progress)
 - Surveys with parents of young children and pregnant and recently pregnant people
- Patient and provider education materials
- Digital partnerships with healthcare provider organizations
- Partnerships with organizations that serve pregnant people
- Social media across CDC's platforms



Thank You